Ascorbate as Prophylaxis and Therapy for COVID-19-Update From Shanghai and U.S. Medical Institutions
Glob Adv Health Med. 2020 Jul 20;9:2164956120934768. doi: 10.1177/2164956120934768
Richard Z Cheng 1, Mikhail Kogan 2 3 4, Devra Davis 5
- COVID-19 patients had low levels of Zinc, Vitamin A, Vitamin D, and Vitamin C – Sept 2021
- Vitamin D, C, A, and E, as well as Iron, Se, and Zinc each augment vaccine response – July 2021
- COVID-19 treatment outside of hospital – Vitamin D, zinc, etc. – May 2021
- Important Role of Micronutrients during COVID-19 (Zinc, Vitamin D, C, Folate) – May 5, 2021
- Many supplements appear to fight COVID-19 – vitamin D cited 52 times – May 2021
- Overview of reviews of COVID-19 and vitamin D, etc. – April 2021
- Micronutrients for COVID-19: Vitamin D, Vitamin C, Melatonin, Zinc, Se, etc. - Dec 2020
- Vitamin C may treat COVID-19 (several studies)
- For COVID-19: Vitamin C use might cause kidney stones, but Vitamin D will not– Aug 8, 2020
- COVID-19 possible therapies: Vitamin D, Selenium, Zinc, Vitamin C, Potassium, Resveratrol , etc.– Aug 5, 2020
- Vitamin C IV, which treats Sepsis, also treats COVID-19 - May 2020
- Does vitamin D (and C) help with Covid-19 - May 2020
- Fight COVID-19 with Vitamin D, Vitamin C, Zinc, Selenium, Resveratrol, etc. - Sardi May 12, 2020
- Common cold prevented and treated by Vitamin D, Vitamin C, Zinc, and Echinacea – review April 2018
Background: No validated treatments have been identified for the COVID-19 pandemic virus; several are currently in randomized clinical trials. Diagnostic instruments are rapidly evolving. Symptoms range from those of a common cold to acute respiratory distress syndrome (ARDS), to sepsis arising from the flood of inflammatory bacterial and viral pathogens in the blood. Mortality generally arises from cytokine storms of uncontrolled inflammation, oxidative injury, and damage to the alveolar-capillary barrier, with secondary bacterial infection. To address the indisputably urgent need for therapeutics for COVID-19, a specialized interdisciplinary medical panel convened in Shanghai in March 2020 to consider all relevant clinical and experimental evidence on the possible utility of intravenous (IV) ascorbate in the treatment of COVID-19-related ARDS.
Methods: The panel convened multidisciplinary medical experts and reviewed all relevant in vitro, in vivo, clinical studies and randomized controlled trials on IV ascorbate and issued a consensus report on 23 March 2020 noting that substantial differences in serum concentrations of ascorbate are achieved through IV administration in contrast with the oral route.
Findings: The Shanghai panel, and a parallel medical group in Guangzhou, are advising the use of high-dose IV ascorbate for the treatment of ARDS, along with other supportive therapies, including Vitamin D and zinc. We report preliminary progress in using this treatment for 50 consecutive cases treated in Shanghai hospitals, consistent with earlier reports from a meta-analysis of the use of IV ascorbate to treat sepsis. We provide an instructive clinical anecdote regarding a single family where one elderly member with cardiac and other major comorbidities developed and survived ARDS-related sepsis following daily treatments that included 15 g of IV ascorbate. None of her adult caregivers who had ingested between 2 and 10 g of ascorbate daily developed COVID-19.